



ASX Company Announcement

Transfer of Patents

30 April 2009

The Directors of Sun Biomedical Limited (ASX Code: SBN) wish to advise that the ownership of the following registered patents has now been transferred from Sun Biomedical Laboratories, Inc. (SBL) to SBN:

US Patent No.	Description
6,046,058	Colour Coded Test Strip
5,962, 336	Multi-Test Panels
6,372,516	Lateral Flow Test Devices
7,041,253	Sample Collection and Test Device
7,300,627	Test Sample Collection System

The patent application (application number 12/313/347) for a Sample Collection Device, known as Oraline 8, has also been transferred.

SBL's US facility will be closed as of 1 May 2009. The Appendix 4C shows cash at the end of the March 2009 quarter of AUD 735k. As previously advised, following the closure of the US facility the balance will be between AUD 400k and AUD 450k.

The Board is currently conducting a review of SBN's operating costs in order to ensure that shareholder value is maximized. This will include the reduction of directors' fees.

The Directors have issued requests for offers for the patents and will provide investors with an update on the progress of this process in June 2009.

For further information in relation to this announcement or any aspects of SBN's operations please visit SBN website at www.sunbiomed.com or contact:

Jim Hallam
Director
Mobile: 0414965442
Email: jim.hallam@turnberryfm.com.au

Sun Biomedical
Limited
ABN 18 001 285 230

Investor Communications
Computershare T: +61 1300 850 505 | F: +61 3 9473 2500 |
E: info@sunbiomed.com

ASX:SBN
www.sunbiomed.com